Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1248Neoplasms 1053Carcinoma, Non-Small-Cell Lung 861Prostatic Neoplasms 703Colorectal Neoplasms 618Lung Neoplasms 586Neoplasm Metastasis 446Multiple Myeloma 427Leukemia, Myeloid, Acute 403Pancreatic Neoplasms 377Ovarian Neoplasms 370Melanoma 324Carcinoma, Hepatocellular 293Recurrence 282Squamous Cell Carcinoma of Head and Neck 277Brain Neoplasms 274Glioblastoma 251Head and Neck Neoplasms 249Stomach Neoplasms 239Carcinoma, Renal Cell 231Precursor Cell Lymphoblastic Leukemia-Lymphoma 230Lymphoma 229Triple Negative Breast Neoplasms 219Hematologic Neoplasms 214Endometrial Neoplasms 213Urinary Bladder Neoplasms 202Lymphoma, Non-Hodgkin 198Uterine Cervical Neoplasms 194Sarcoma 192Glioma 190

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Malignant Peripheral Nerve Sheath Tumors × 90 days × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡